Trials / Completed
CompletedNCT04672356
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, phase I clinical study to evaluate the efficacy, tolerability and safety of recombinant fully human anti-TIGIT antibody (IBI939) in combination with recombinant fully human anti-programmed cell death receptor 1 (PD-1) antibody (sintilimab) in subjects with advanced lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI939 | IBI939 injection |
| BIOLOGICAL | Sintilimab | Sintilimab injection |
Timeline
- Start date
- 2021-01-25
- Primary completion
- 2023-01-01
- Completion
- 2023-06-01
- First posted
- 2020-12-17
- Last updated
- 2023-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04672356. Inclusion in this directory is not an endorsement.